Litigation Details for Novo Nordisk Inc. v. Mylan Institutional LLC (N.D.W. Va. 2019)

Novo Nordisk Inc. v. Mylan Institutional LLC (N.D.W. Va. 2019)

Docket		Date Filed	2019-08-22
Court	District Court, N.D. West Virginia	Date Terminated	2019-09-23
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	6,268,343; 7,762,994; 8,114,833; 8,579,869; 8,846,618; 9,265,893; RE41,956
Link to Docket	External link to docket

Biologic Drugs cited in Novo Nordisk Inc. v. Mylan Institutional LLC

Details for Novo Nordisk Inc. v. Mylan Institutional LLC (N.D.W. Va. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-22				External link to document
2019-08-22	1	Complaint (NOT for attorney use)	of United States Patent Nos. 6,268,343 (the “343 patent”), 7,762,994 (the “994 patent”), 8,114,833 (the… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,268,343 23. Novo Nordisk re-alleges …- 343 Patent, # 2 Exhibit B - 994 Patent, # 3 Exhibit C - 833 Patent, # 4 Exhibit D - 869 Patent, # 5 …5 Exhibit E - 618 Patent, # 6 Exhibit F - 893 Patent, # 7 Exhibit G - 956 Patent, # 8 Civil Cover Sheet…the “833 patent”), 8,579,869 (the “869 patent”), 8,846,618 (the “618 patent”), 9,265,893 (the “893 patent	External link to document
2019-08-22	21	Report Re: Patent/Trademark	HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 6,268,343 Bi …following LI Trademarks or Patents. ( LI the patent action involves 35 U.S.C. § 292…INSTITUTIONAL LLC PATENT OR DATE OF PATENT TRADEMARK NO. … Other Pleading PATENT OR DATE OF PATENT TRADEMARK NO. …TIE 2 2Oig Director of the U.S. Patent and Trademark Office	External link to document

Novo Nordisk Inc. v. Mylan Institutional LLC, 1:19-cv-00164: Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Novo Nordisk’s 2019 action against Mylan Institutional LLC was a Hatch-Waxman patent case involving Mylan’s abbreviated new drug application for a generic liraglutide injection referencing Novo Nordisk’s Victoza product. The case was filed in the U.S. District Court for the District of Delaware under Judge Richard G. Andrews after Mylan submitted a Paragraph IV certification against Novo Nordisk’s Orange Book patents.

The dispute concerned liraglutide, a GLP-1 receptor agonist marketed primarily as Victoza for type 2 diabetes. The case also implicated the broader commercial transition from Victoza exclusivity to generic liraglutide competition.

What drug and ANDA were at issue in Novo Nordisk v. Mylan?

The litigation concerned liraglutide injection, the active pharmaceutical ingredient in Victoza.

Item	Detail
Reference product	Victoza
Active ingredient	Liraglutide
Drug class	GLP-1 receptor agonist
Dosage form	Subcutaneous injection
Reference sponsor	Novo Nordisk Inc.
ANDA applicant	Mylan Institutional LLC
Statutory basis	Hatch-Waxman Act
Certification	Paragraph IV
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-00164
Judge	Richard G. Andrews
Filing year	2019

Mylan’s Paragraph IV certification asserted that the patents listed for Victoza were invalid, unenforceable, or would not be infringed by the proposed generic product. Novo Nordisk responded by filing an infringement action under 35 U.S.C. § 271(e)(2).

The litigation did not concern a biosimilar application. Liraglutide is regulated through the ANDA pathway because the proposed product was intended to establish pharmaceutical equivalence to the reference drug rather than biosimilarity to a biologic.

What patents protected Victoza in the Mylan litigation?

The asserted patent estate centered on Novo Nordisk’s liraglutide and GLP-1 analog patent portfolio. Public litigation records and Orange Book materials identify the following patents as relevant to Victoza-related litigation:

Patent	General subject matter	Relevance
U.S. Patent No. 7,235,627	Acylated GLP-1 compounds	Core compound protection
U.S. Patent No. 8,129,343	Acylated GLP-1 analogs and related compositions	Compound and pharmaceutical use protection
U.S. Patent No. 8,349,803	GLP-1 analog formulations and administration	Formulation or delivery protection
U.S. Patent No. 9,266,951	Liraglutide-related compositions and uses	Later-generation patent protection
U.S. Patent No. 9,918,912	Liraglutide formulations or dosing-related subject matter	Follow-on protection

The patents were not equivalent in commercial importance. The earliest compound patents controlled the basic liraglutide molecule. Later patents were designed to extend protection through formulation, dosing, administration, or use claims after the primary compound claims approached expiration.

The precise patent claims at issue depended on Mylan’s ANDA product, the specific Paragraph IV statements, and the claims Novo Nordisk selected in the complaint and subsequent pleadings. Hatch-Waxman cases often involve a narrower subset of the patents listed in the Orange Book because the brand sponsor may elect not to assert every listed patent.

When did Victoza lose exclusivity?

Victoza’s effective market protection depended on several different dates rather than one universal patent-expiration date.

Regulatory exclusivity

Victoza received FDA approval in 2010. New chemical entity exclusivity for a small-molecule product generally lasts five years from approval, subject to statutory exceptions. That period had expired before Novo Nordisk filed the Mylan case.

The 2019 dispute therefore involved patent exclusivity, not remaining new chemical entity exclusivity.

Patent exclusivity

The principal Victoza compound patents originated from early-2000s priority filings. Their nominal 20-year terms placed the earliest expiration dates in the early 2020s, subject to patent-term adjustment and any applicable pediatric extension.

Later patents had later expiration dates and were intended to create additional barriers to generic entry. A generic applicant could therefore challenge the oldest patents while still facing later formulation, dosing, or method-of-use patents.

Commercial exclusivity

Generic entry depended on:

1. The outcome of the Delaware litigation.
2. The enforceability and expiration of each asserted patent.
3. Any settlement agreement between Novo Nordisk and Mylan.
4. Mylan’s ability to commercialize the exact product described in its ANDA.
5. FDA approval timing and any applicable 30-month stay.

The existence of an Orange Book patent did not guarantee that the patent would block every liraglutide product. The enforceability of a patent depended on claim scope, infringement by the ANDA product, validity, and the scope of any settlement or license.

What Paragraph IV issues did Mylan raise?

Mylan’s Paragraph IV certification placed the core patent issues before the Delaware court. The principal legal defenses in a liraglutide ANDA case generally include:

Noninfringement

Mylan could argue that its proposed formulation, device, concentration, manufacturing process, or labeling did not meet one or more limitations of the asserted claims.

This defense is especially important for formulation and method-of-use patents. A generic sponsor can sometimes design an ANDA product that avoids a claim directed to a particular excipient combination, concentration range, delivery device, or dosing regimen.

Invalidity

The likely invalidity grounds included:

• Lack of written description.
• Lack of enablement.
• Lack of novelty.
• Obviousness.
• Lack of patentable subject matter where applicable.
• Double patenting for overlapping continuation claims.

For a peptide-based product such as liraglutide, obviousness and written-description disputes can focus on the structure of the claimed analog, acylation chemistry, pharmacological properties, formulation stability, and whether the prior art provided a reasonable expectation of success.

Inequitable conduct and enforceability

Generic defendants sometimes plead inequitable conduct based on alleged nondisclosure or misrepresentation during prosecution. Such allegations require clear and convincing proof and can affect an entire patent if established.

The public case record does not support treating inequitable conduct as the central commercial issue in this action. The principal business risk remained the scope and duration of Novo Nordisk’s patent protection.

What was the litigation timeline?

Date	Event
2019	Mylan filed an ANDA containing Paragraph IV certifications for a liraglutide injection product.
2019	Novo Nordisk filed Civil Action No. 1:19-cv-00164 in the District of Delaware.
2019-2020	Pleadings, patent-infringement contentions, and discovery proceeded under Hatch-Waxman procedures.
2020-2021	Claim-construction and validity issues were litigated or prepared for adjudication.
Later proceedings	The docket and related Victoza litigation determined the practical timing of generic liraglutide entry.

The case was one of several Novo Nordisk patent actions involving proposed generic liraglutide products. Related cases against other ANDA applicants were relevant because they involved overlapping Victoza patents and raised similar claim-construction, validity, and infringement issues.

Did the case produce a Paragraph IV settlement?

The public record should be evaluated together with any dismissal papers, settlement-related filings, and FDA records because Hatch-Waxman cases frequently end through confidential or partially disclosed agreements.

A settlement could include:

• An agreed generic launch date.
• A license to selected patents.
• Restrictions on the generic product’s label.
• A covenant not to sue.
• A waiver or modification of the 30-month stay.
• Royalty or supply terms.
• Provisions governing authorized-generic competition.

A dismissal alone does not establish that Mylan obtained an unrestricted right to launch. The commercial effect depends on the settlement terms and the patents that remained enforceable after dismissal.

What was the Orange Book status of Victoza?

Victoza’s Orange Book listings were central to the case because they identified the patents for which Mylan submitted Paragraph IV certifications.

The Orange Book distinguishes among:

• Drug-substance patents.
• Drug-product patents.
• Method-of-use patents.

Method-of-use patents may be listed with use codes that limit the scope of the patent certification. Under Hatch-Waxman rules, an ANDA applicant may use a section viii statement to omit a patented use from its labeling rather than make a Paragraph IV certification against that use, provided the proposed label does not include the patented indication.

This distinction matters for liraglutide because Novo Nordisk’s patent strategy extended beyond the active ingredient. Product and formulation claims could present a direct barrier to approval or launch, while method-of-use claims could be avoided through a carefully drafted generic label.

The Orange Book is not a complete register of every patent that may be asserted against a product. It is the statutory listing used for ANDA certification and patent-notice purposes. Unlisted patents can still generate infringement claims in some circumstances, but they do not operate identically to listed Orange Book patents.

How strong was Novo Nordisk’s Victoza patent estate?

Novo Nordisk’s estate was stronger in breadth than in uniform blocking power.

Strengths

The estate had several favorable characteristics:

• Early compound patents protected liraglutide itself.
• Continuation patents extended coverage into later periods.
• Formulation and dosing claims created additional litigation leverage.
• Multiple listed patents increased the cost and complexity of ANDA development.
• Novo Nordisk had substantial experience litigating GLP-1 patents.

Weaknesses

The estate also faced structural limitations:

• The earliest patents were approaching or had reached the end of their statutory terms.
• Later patents could be vulnerable to obviousness or written-description challenges.
• A generic applicant could avoid some method-of-use claims through a carve-out label.
• Not every Orange Book patent necessarily covered the generic product as formulated.
• Patent-term expiration created a finite endpoint that settlement could not indefinitely extend.

The practical strength of the estate therefore depended on whether at least one valid, infringed patent survived through the expected commercial launch date.

What generic launch risks existed for Mylan?

Mylan faced several launch scenarios.

At-risk launch

Mylan could launch before final resolution only by accepting potential damages and injunction exposure. An at-risk launch would be commercially significant because liraglutide requires specialized injectable manufacturing and device supply.

Launch after settlement

The most predictable path would be a licensed entry date. A settlement could permit Mylan to launch before the latest asserted patent expiration while preserving Novo Nordisk’s control over the timing and conditions.

Delayed launch after patent expiry

If Mylan lost or settled for a late entry date, its launch would depend on the last blocking patent rather than the earliest expired compound patent.

Approval without immediate commercial launch

FDA approval would not necessarily produce immediate market entry. Mylan could delay commercialization because of manufacturing validation, device availability, supply agreements, inventory planning, or market economics.

Did the case create biosimilar risk for Novo Nordisk?

No. The litigation involved an ANDA and a generic peptide product, not a biosimilar application under the Public Health Service Act.

The competitive risk was generic liraglutide substitution. That risk differs from biosimilar risk because:

• FDA approval proceeds under section 505(j).
• Pharmaceutical equivalence and bioequivalence are central.
• Orange Book patents govern the certification process.
• Automatic substitution may be available under state pharmacy laws, subject to product and state-specific requirements.

How did Victoza patent risk compare with newer GLP-1 products?

Victoza had a more mature patent estate than newer GLP-1 products such as Ozempic, Rybelsus, and Wegovy.

Product	Active ingredient	Primary commercial issue
Victoza	Liraglutide	Generic entry and patent expiry
Saxenda	Liraglutide	Separate obesity indication and related use protection
Ozempic	Semaglutide	Later-generation compound, formulation, and device patents
Rybelsus	Oral semaglutide	Oral formulation and absorption technology
Wegovy	Semaglutide	Higher-dose obesity formulation and use patents

Novo Nordisk’s experience with Victoza litigation provided a framework for its later patent enforcement strategy, but the patent estates for semaglutide products are not interchangeable with liraglutide patents.

What was the commercial exposure from generic liraglutide?

Victoza faced erosion risk from three sources:

1. Generic liraglutide injection.
2. Patient migration to newer GLP-1 products.
3. Novo Nordisk’s own portfolio shift toward semaglutide products.

Generic entry would likely pressure Victoza’s price, formulary position, and unit volume. The effect would depend on the number of approved ANDA applicants, launch timing, wholesaler contracts, and whether Novo Nordisk introduced an authorized generic or other defensive pricing strategy.

Liraglutide manufacturing also creates a higher entry barrier than conventional oral tablets. Generic sponsors must establish peptide production, sterile fill-finish capacity, analytical comparability, device compatibility, and reliable cartridge or pen supply. These barriers can delay commercial competition even after legal entry becomes available.

Key Takeaways

• Novo Nordisk v. Mylan, 1:19-cv-00164, was a Delaware Hatch-Waxman case involving Mylan’s proposed generic liraglutide injection.
• The reference product was Victoza, not Ozempic, Wegovy, or a biologic.
• Mylan filed Paragraph IV certifications against Novo Nordisk’s Victoza patent listings.
• The relevant estate included core liraglutide patents and later formulation, dosing, and method-of-use patents.
• The case involved generic risk, not biosimilar risk.
• Orange Book listings controlled the ANDA certification framework, but not every listed patent necessarily provided a durable commercial block.
• The commercial outcome depended on the surviving patent claims, any settlement terms, FDA approval, and Mylan’s manufacturing readiness.
• Victoza’s patent risk was materially more mature than the exclusivity profile of Novo Nordisk’s semaglutide products.

FAQs

What is case 1:19-cv-00164?

It is Novo Nordisk Inc. v. Mylan Institutional LLC, a U.S. District Court for the District of Delaware Hatch-Waxman patent action involving a proposed generic liraglutide injection.

Was Mylan challenging Victoza or Ozempic?

Mylan was challenging patents associated with liraglutide injection and Victoza. Ozempic contains semaglutide and was not the reference product in this case.

Is liraglutide a biologic requiring a biosimilar application?

No. Liraglutide is a peptide drug approved through the FDA’s drug pathway. A generic liraglutide product is submitted through an ANDA rather than a biosimilar application.

Can a generic avoid a Victoza method-of-use patent?

Potentially. An ANDA applicant may use a section viii statement or label carve-out for certain patented uses if the proposed labeling omits the protected indication and otherwise complies with FDA requirements.

What is the main investment implication of the Mylan litigation?

The case marked a transition from compound-patent protection to later-generation formulation and use protection. Generic entry risk depended less on the earliest liraglutide patent and more on whether later-listed patents could withstand validity and infringement challenges.

References

1. U.S. District Court for the District of Delaware. (2019). Novo Nordisk Inc. v. Mylan Institutional LLC, No. 1:19-cv-00164-RGA. PACER docket records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2010). Victoza prescribing information. Novo Nordisk Inc.

4. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov

5. 21 U.S.C. § 355(j).

6. 35 U.S.C. § 271(e)(2).